Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Doxercalciferol→

Doxercalciferol Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
54573-75-0
PubChem CID
5281107
Molecular formula
C28H44O2
Molecular weight
412.6 g/mol
Drug class
Vitamin D2 Analog
Mechanism of action
Doxercalciferol is a synthetic vitamin D 2 analog that requires metabolic activation to form the active 1α,25-(OH) 2 D 2 metabolite, which binds to the vitamin D receptor (VDR) to result in the selective activation of vitamin D responsive pathways.
Indications / reported uses
  • Hyperparathyroidism
  • secondary hyperparathyroidism in adult patients with Stage 3 or Stage 4 chronic kidney disease (CKD) and adult patients with CKD on dialysis
  • secondary hyperparathyroidism in adult patients with chronic kidney disease (CKD) on dialysis
  • secondary hyperparathyroidism in adult patients with CKD on dialysis

Sources: FDA product labels (openFDA) · FDA product information

Identification source: PubChem record (CID 5281107). The linked PubChem record is provided for identity reference. Confirm the exact salt, hydrate, isomer, mixture, or product form against authoritative source documentation when defining the assessment scope.

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Doxercalciferol Environmental Risk Assessment (ERA) (the Doxercalciferol ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.